BPC
KRYS icon

Bryce Point Capital’s Krystal Biotech KRYS Stock Holding History

Bryce Point Capital’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,323
Closed -$594K – 219
2025
Q2 		$594K Buy
4,323
+37
+0.9% +$5.43K 0.5% 127
2025
Q1 		$790K Buy
+4,286
New +$721K 0.59% 95

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bryce Point Capital's KRYS Position: Q3 2025 in Review

Bryce Point Capital sold out of Krystal Biotech (KRYS) in Q3 2025, closing a stake of 4,323 shares — an estimated $594K sold.

Bryce Point Capital first reported a position in KRYS in Q1 2025 and held it in 2 quarters. The position peaked at $790K in Q1 2025. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

  • Bryce Point Capital reported no remaining Krystal Biotech position as of Q3 2025 after selling out during the quarter.
  • Bryce Point Capital sold 4,323 Krystal Biotech shares in Q3 2025, an estimated $594K.
  • Bryce Point Capital first reported a position in Krystal Biotech in Q1 2025 and held it in 2 quarters.
  • Bryce Point Capital's Krystal Biotech position peaked at $790K in Q1 2025.
  • 284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.